Sounds very similar to the strategy that UNS have been talking about with their needles - using their retractable sryringe to help defeat generic competition.
The Roche drugs are in the cancer/arthritis class so aren't included in the Sanofi exclusivity contract. I'd be willing to bet that Roche is the next company to partner with UNS - of course they won't announce anything until the final deal is done - exclusivity over those classes.
That sounds like confirmation that 1) there is a problem and 2) they have a solution.
I haven't heard of anyone else coming up with a defence stategy for generics so I think UNS is the logical answer.
- Forums
- ASX - By Stock
- UNS
- is roche next
is roche next, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online